Challenges for managing overactive bladder and guidance for patient support.
OBJECTIVE
Describe challenges to improving management of overactive bladder (OAB) outcomes and summarize research findings on critical success factors for supporting OAB treatment.


METHODS
A multidisciplinary team collected primary and secondary data, including an OAB-specific survey; a literature review; and an expert panel discussion.


METHODS
A US survey of patients who were prescribed antimuscarinics included topics related to OAB, such as reasons for medication discontinuation. The PubMed database was searched for articles published in the past 10 years on OAB treatment and adherence, and additional publications were reviewed related to health behavior change models. An expert panel reviewed findings and provided perspective.


RESULTS
The survey (n = 5392) showed that, among patients discontinuing OAB medications, 45.4% reported unmet treatment expectations as the reason for discontinuation. Literature review findings supported intervention at the beginning of OAB treatment, specific messages to increase treatment adherence, and involving the healthcare stakeholders most trusted by patients. Implications of OAB patient support were drawn from reviews of the Transtheoretical Model, the Health Belief Model, and social learning theory. The expert panel highlighted desirable attributes of OAB patient education delivered in the medical care setting.


CONCLUSIONS
Challenges to improving OAB symptom burden and outcomes include underdiagnosis, undertreatment, and patient nonadherence with medications. Patient support of medication adherence may be enhanced by simultaneously supporting the use of nonpharmaceutical lifestyle modifications and behavioral interventions. Healthcare providers acknowledge the need for patient education but lack the time and resources to deliver interventions or monitor patients' progress outside the medical office. Patient support may be achieved through external programs that complement patient-physician interactions.
Schabert
Vernon F
VF
IMS Health, Inc, Health Economics and Outcomes Research, 300 N Washington St, Ste 300, Falls Church, VA 22046, USA. VSchabert@us.imshealth.com
Bavendam
Tamara
T
Goldberg
Erica L
EL
Trocio
Jeffrey N
JN
Brubaker
Linda
L
D006801:Humans; D055118:Medication Adherence; D018727:Muscarinic Antagonists / Q000627:therapeutic use*; D012944:Social Support; D011795:Surveys and Questionnaires; D016312:Treatment Refusal; D014481:United States; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*
D018727:Muscarinic Antagonists